Edda Simoncini

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)

Bernhard C. Pestalozzi, David Zahrieh, Karen N. Price et al. · Annals of Oncology · 2006 · 412 citations · Full text

Medicine, Neurology, Oncology +16

Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII

Diana Crivellari, Marco Bonetti, Monica Castiglione‐Gertsch et al. · Journal of Clinical Oncology · 2000 · 295 citations

Medicine, Oncology, Pharmacology +15

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience

Gilles Berclaz, S. Li, Karen N. Price et al. · Annals of Oncology · 2004 · 260 citations · Full text

Medicine, Oncology, Surgery +9

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI

Olivia Pagani, Anne O’Neill, M. Castiglione et al. · European Journal of Cancer · 1998 · 227 citations

Medicine, Oncology, Pharmacology +14